|
|
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #REDIRECT[[Rifampin]] |
| |authorTag={{KS}}
| |
| |aOrAn=a
| |
| |adverseReactions=<!--Black Box Warning-->
| |
| |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
| |
| | |
| * Content
| |
| | |
| <!--Adult Indications and Dosage-->
| |
| | |
| <!--FDA-Labeled Indications and Dosage (Adult)-->
| |
| |fdaLIADAdult======Condition1=====
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition2=====
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition3=====
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition4=====
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| <!--Off-Label Use and Dosage (Adult)-->
| |
| | |
| <!--Guideline-Supported Use (Adult)-->
| |
| |offLabelAdultGuideSupport======Condition1=====
| |
| | |
| * Developed by:
| |
| | |
| * Class of Recommendation:
| |
| | |
| * Strength of Evidence:
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition2=====
| |
| | |
| There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| |
| | |
| <!--Non–Guideline-Supported Use (Adult)-->
| |
| |offLabelAdultNoGuideSupport======Condition1=====
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition2=====
| |
| | |
| There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| |
| | |
| <!--Pediatric Indications and Dosage-->
| |
| | |
| <!--FDA-Labeled Indications and Dosage (Pediatric)-->
| |
| |fdaLIADPed======Condition1=====
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition2=====
| |
| | |
| There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
| |
| | |
| <!--Off-Label Use and Dosage (Pediatric)-->
| |
| | |
| <!--Guideline-Supported Use (Pediatric)-->
| |
| |offLabelPedGuideSupport======Condition1=====
| |
| | |
| * Developed by:
| |
| | |
| * Class of Recommendation:
| |
| | |
| * Strength of Evidence:
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition2=====
| |
| | |
| There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
| |
| | |
| <!--Non–Guideline-Supported Use (Pediatric)-->
| |
| |offLabelPedNoGuideSupport======Condition1=====
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition2=====
| |
| | |
| There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
| |
| | |
| <!--Contraindications-->
| |
| |contraindications=* Condition1
| |
| | |
| <!--Warnings-->
| |
| |warnings=* Description
| |
| | |
| ====Precautions====
| |
| | |
| * Description
| |
| | |
| <!--Adverse Reactions-->
| |
| | |
| <!--Clinical Trials Experience-->
| |
| |clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
| |
| | |
| =====Body as a Whole=====
| |
| | |
| | |
| | |
| | |
| =====Cardiovascular=====
| |
| | |
| | |
| | |
| | |
| =====Digestive=====
| |
| | |
| | |
| | |
| | |
| =====Endocrine=====
| |
| | |
| | |
| | |
| | |
| =====Hematologic and Lymphatic=====
| |
| | |
| | |
| | |
| | |
| =====Metabolic and Nutritional=====
| |
| | |
| | |
| | |
| | |
| =====Musculoskeletal=====
| |
| | |
| | |
| | |
| | |
| =====Neurologic=====
| |
| | |
| | |
| | |
| | |
| =====Respiratory=====
| |
| | |
| | |
| | |
| | |
| =====Skin and Hypersensitivy Reactions=====
| |
| | |
| | |
| | |
| | |
| =====Special Senses=====
| |
| | |
| | |
| | |
| | |
| =====Urogenital=====
| |
| | |
| | |
| | |
| | |
| =====Miscellaneous=====
| |
| | |
| | |
| | |
| <!--Postmarketing Experience-->
| |
| |postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
| |
| | |
| =====Body as a Whole=====
| |
| | |
| | |
| | |
| =====Cardiovascular=====
| |
| | |
| | |
| | |
| =====Digestive=====
| |
| | |
| | |
| | |
| =====Endocrine=====
| |
| | |
| | |
| | |
| =====Hematologic and Lymphatic=====
| |
| | |
| | |
| | |
| =====Metabolic and Nutritional=====
| |
| | |
| | |
| | |
| =====Musculoskeletal=====
| |
| | |
| | |
| | |
| =====Neurologic=====
| |
| | |
| | |
| | |
| =====Respiratory=====
| |
| | |
| | |
| | |
| =====Skin and Hypersensitivy Reactions=====
| |
| | |
| | |
| | |
| =====Special Senses=====
| |
| | |
| | |
| | |
| =====Urogenital=====
| |
| | |
| | |
| | |
| =====Miscellaneous=====
| |
| | |
| | |
| | |
| <!--Drug Interactions-->
| |
| |drugInteractions=* Drug
| |
| :* Description
| |
| | |
| <!--Use in Specific Populations-->
| |
| |useInPregnancyFDA=* '''Pregnancy Category'''
| |
| |useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
| |
| | |
| There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
| |
| |useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
| |
| |useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
| |
| |useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
| |
| |useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
| |
| |useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
| |
| |useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
| |
| |useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
| |
| |useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
| |
| |useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
| |
| |useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
| |
| | |
| <!--Administration and Monitoring-->
| |
| |administration=* Oral
| |
| | |
| * Intravenous
| |
| |monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
| |
| | |
| * Description
| |
| | |
| <!--IV Compatibility-->
| |
| |IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Overdosage-->
| |
| |overdose====Acute Overdose===
| |
| | |
| ====Signs and Symptoms====
| |
| | |
| * Description
| |
| | |
| ====Management====
| |
| | |
| * Description
| |
| | |
| ===Chronic Overdose===
| |
| | |
| There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Pharmacology-->
| |
| | |
| <!--Drug box 2-->
| |
| |drugBox=<!--Mechanism of Action-->
| |
| |mechAction=*
| |
| | |
| <!--Structure-->
| |
| |structure=Rifampin capsules, USP for oral administration contain 150 mg or 300 mg rifampin per capsule. The 150 mg and 300 mg capsules also contain, as inactive ingredients: colloidal silicon dioxide, corn starch, FD&C Blue No. 1, FD&C Red No. 40, gelatin, lactose monohydrate, magnesium stearate, sodium lauryl sulfate, talc, and titanium dioxide.
| |
| | |
| The printing ink contains ammonium hydroxide, isopropyl alcohol, n-butyl alcohol, pharmaceutical glaze, propylene glycol, simethicone, and titanium dioxide
| |
| | |
| Rifampin is a semisynthetic antibiotic derivative of rifamycin SV. Rifampin is a red-brown crystalline powder very slightly soluble in water at neutral pH, freely soluble in chloroform, soluble in ethyl acetate and in methanol. Its molecular weight is 822.95 and its chemical formula is C43H58N4O12.
| |
| | |
| The chemical name for rifampin is either:
| |
| | |
| 3-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin
| |
| | |
| or
| |
| 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate.
| |
| | |
| Its structural formula is:
| |
| | |
| [[File:Rifampin structure.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
| |
| | |
| | |
| |PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
| |
| | |
| | |
| |PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Nonclinical Toxicology-->
| |
| |nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Clinical Studies-->
| |
| |clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--How Supplied-->
| |
| |howSupplied=*
| |
| |packLabel=<!--Patient Counseling Information-->
| |
| |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Precautions with Alcohol-->
| |
| |alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
| |
| | |
| <!--Brand Names-->
| |
| |brandNames=* ®<ref>{{Cite web | title = | url = }}</ref>
| |
| | |
| <!--Look-Alike Drug Names-->
| |
| |lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher = | date = }}</ref>
| |
| | |
| <!--Drug Shortage Status-->
| |
| |drugShortage=
| |
| }}
| |
| {{PillImage
| |
| |fileName=No image.jpg
| |
| }}
| |
| {{LabelImage
| |
| |fileName={{PAGENAME}}11.png
| |
| }}
| |
| {{LabelImage
| |
| |fileName={{PAGENAME}}11.png
| |
| }}
| |
| <!--Pill Image-->
| |
| | |
| | |
| | |
| <!--Label Display Image-->
| |
| | |
| | |
| | |
| | |
| | |
| <!--Category-->
| |
| | |
| [[Category:Drug]]
| |